Real world data about stupp platform in the treatment of glioblastoma in a single center of Colombia.

person Erick Andres Cantor Rizo ICCAL Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia info_outline Erick Andres Cantor Rizo, Javier Segovia, Luis Eduardo Pino, Henry Vargas, Ivan Triana, John Alejandro Murillo Silva, Aylen Vanessa Ospina Serrano

Authors person Erick Andres Cantor Rizo ICCAL Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia info_outline Erick Andres Cantor Rizo, Javier Segovia, Luis Eduardo Pino, Henry Vargas, Ivan Triana, John Alejandro Murillo Silva, Aylen Vanessa Ospina Serrano Organizations ICCAL Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, Fundación Santa Fe de Bogota, Bogotá, Colombia, ICCAL Hospital Universitario Fundación Santa Fe de Bogotá, Bogota, Colombia, ICCAL fundacion Santa Fe de Bogota, Bogotá, Colombia Abstract Disclosures Research Funding Institutional Funding ICCAL Fundacion Santafe De Bogota Background: Glioblastoma cancer is a disease with high mortality reported worldwide. However, in Colombia and Latin America there is a large gap in terms of the information available regarding the characteristics and survival of these patients. Methods: This is an observational, descriptive study of a cohort of patients with glioblastoma cancer who initiated medical treatment at Fundación Santa Fe de Bogotá, a high complexity hospital. We analyzed clinical characteristics, IDH mutation, histology, treatments, progression free survival (PFS), overall survival (OSm) and treatment related complications. We use Kaplan Meier as survival statistic. Results: Twenty patients were included during the 48 months. The average age was 62 years. 65% males, 35% female. IDH mutation detection was performed in 100% of patients, and IDH1 was positive in 20% of the population. Regarding the anatomy location occipital lobe 5%, temporal 20%, parietal 5%, frontal 35%, other locations 35%, ECOG 0-1 were the 100%. Time from start to stupp platform after surgery was 6.1 weeks. All patients received the surgical treatment scheme, later stupp platform followed by temozolamide. In the survival analysis, 15% of patients died during follow-up and 35% progressed to first line. The median overall survival (OSm) 19m, and Progression-free survival (PFS) 14m for the global population. Adjusting survival models for confounding variables, in males the OSm 19 and 15.6m in females. The PDF 15,6m males and 11.8m in females. The OSm in patients with IDH negative 20m, and in the group with IDH1 mutated the OSm has not been reached to 18m of follow-up. Conclusions: Our cohort of patients is similar to the literature reported worldwide, gender may be a predictor of risk. We have good survival times with the stupp platform, rapid access to treatment may be a factor in favor of our good outcomes.